Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 February 2015 |
Main ID: |
NCT00004380 |
Date of registration:
|
18/10/1999 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis
|
Scientific title:
|
|
Date of first enrolment:
|
December 1991 |
Target sample size:
|
1 |
Recruitment status: |
Completed |
URL:
|
http://clinicaltrials.gov/show/NCT00004380 |
Study type:
|
Interventional |
Study design:
|
Allocation: Non-Randomized, Primary Purpose: Treatment
|
Phase:
|
Phase 2
|
|
Contacts
|
Name:
|
G. Scott Herron |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Stanford University |
| | |
Key inclusion & exclusion criteria
|
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Progressive systemic sclerosis (scleroderma)
- No pregnant or nursing women
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Systemic Sclerosis
|
Intervention(s)
|
Drug: relaxin
|
Secondary ID(s)
|
SUMC-37488
|
199/12015
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|